CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics ...

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...

ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody ...

ProMIS Neurosciences ( ($PMN) ) has provided an announcement. On December 12, 2025, ProMIS Neurosciences Inc. announced it has regained compliance ...

Guggenheim analyst Eddie Hickman lowered the firm’s price target on ProMIS Neurosciences (PMN) to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences’ Alzheimer’s candidate, PMN310, ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

ProMIS Neurosciences (NASDAQ:PMN) announced in vitro preclinical data that showed differentiation of PMN310 from other amyloid-beta-directed antibodies at the International Conference on Alzheimer’s ...

ProMIS Neurosciences shares surged after the company said the Food and Drug Administration granted a fast-track designation to the company's in-development treatment for Alzheimer's disease. Shares ...

Purpose This study investigated the PROMIS Self-Efficacy Measure for Managing Chronic Conditions (PROMIS-SE) domain distributions and examined the factor structure of the PROMIS-SE. Methods A total of ...